

9-9-02

PATENT  
674542-2002

1645

RECEIVED  
SEP 10 2002  
TECH CENTER 1600  
1645

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : NIELSEN et al.  
 U.S. Serial No. : 10/080,101  
 Filed : February 19, 2002  
 For : SYNTHETIC VACCINE AGENTS  
 Examiner : To Be Assigned  
 Art Unit : 1645

745 Fifth Avenue  
 New York, NY 10151

EXPRESS MAIL

Mailing Label Number: EV073654658US

Date of Deposit: September 6, 2002

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 CFR 1.10 on the date indicated above and is addressed to: Commissioner for Patents, Washington, D.C. 20231.

Charles Jackson  
 (Typed or printed name of person mailing paper or fee)

Charles Jackson  
 (Signature of person mailing paper or fee)

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
 Washington, D.C. 20231

Sir:

The Examiner's attention is respectfully drawn to the enclosed documents listed on the accompanying PTO form 1449.

Also enclosed is a copy of the International Search Report for the corresponding PCT application (PCT/DK02/00112), which was mailed on March 9, 2002. A copy of each of the references cited therein is enclosed.

As this Information Disclosure Statement is being filed before the mailing of the first Office Action, it is believed that no fee is required for entry of this paper. However, the


Commissioner is hereby authorized to charge any such fee, or credit any overpayment to Deposit Account 50-0230.

The filing of this Information Disclosure Statement is not an admission that the documents identified herein constitute prior art to the present application.

Applicants respectfully request that the Examiner considers and makes of record the documents cited herewith and that a copy of Form PTO-1449 be initialed by the Examiner and returned to the undersigned.

Respectfully submitted,

FROMMER LAWRENCE & HAUG LLP  
Attorneys for Applicants

By: 

Thomas J. Kowalski  
Reg. No. 32,147  
(212) 588-0800

<p>Based on Form PTO-1449 (3/90)</p> <p>O I P E SEP 06 2002 PATENT &amp; TRADEMARK OFFICE U.S. GOVERNMENT</p> <p>LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)</p>	ATTY. DOCKET NO.	SERIAL NO. 10/080145
	674542-2003	
	APPLICANT	NIELSEN et al.
	FILING DATE	GROUP
February 19, 2002		

RECEIVED  
FEB 10 2002  
TECH CENTER 1600/2900  
10/080145

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	US 5,874,469	2/23/99	Maniar et al.			
	AB	US 4,608,251	8/26/86	Mia			
	AC	US 4,601,903	7/22/86	Frasch			
	AD	US 4,599,231	7/8/86	Milich et al.			
	AE	US 4,599,230	7/8/86	Milich et al.			
	AF	US 4,596,792	6/24/86	Vyas			
	AG	US 4,578,770	3/25/86	Mitani			
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
	AL	WO 95/05849	3/2/95	WIPO			
	AM	WO 94/03530	02/17/94	WIPO			
	AN	WO 00/20027	04/13/00	WIPO			
	AO	WO 95/07707	3/23/95	WIPO			
	AP	WO 00/65058	11/2/00	WIPO			

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AQ		Gregorius and Theisen, "In Situ Deprotection: A method for Covalent Immobilization of Peptides with well-defined orientation for use in solid phase immunoassays such as enzyme-linked immunosorbent assay" (2001) Analytical Biochemistry 299: 84-91
AR		Barr and Mitchell, "ISCOMs (immunostimulating complexes): The first decade" Immunology and Cell Biology (1996) 74: 8-25.
AS		Gosselin et al. "Enhanced Antigen Presentation using Human Fc $\square$ Receptor (Monocyte/Macrophage)-specific immunogens" (1992) 149:3477-3481
AT		Nilsson and Mosbach (1987) "Supports for Enzyme Immobilization" Methods in Enzymology 135: 67
AU		Hermansson et al. "Immobilized affinity ligand techniques" (1992) 87.
AV		Morein et al. "Immunostimulating Complexes, Clinical Potential in Vaccine Development" Clin. Immunotherapy (1995) 3(6):460-475

EXAMINER	DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Based on Form PTO-1449 (3/90)  LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	SERIAL NO.
	674542-2003	10/089,101
	APPLICANT	NIELSEN et al.
	FILING DATE	GROUP
February 19, 2002		1645

*O I P E SCIS*  
SEP 06 2002  
PATENT & TRADEMARK OFFICE  
AUG 2002

RECEIVED  
TECH CENTER 1600  
SEP 18 2002  
2002

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
	AW	WO 00/05316	2/3/00	WIPO			
	AX	WO 98/23635	6/4/98	WIPO			
	AY	WO 93/15760	8/19/93	WIPO			
	AZ	WO 93/23076	11/25/93	WIPO			

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	BA	Irving et al. " Random-peptide libraries and antigen-fragment libraries for epitope mapping and the development of vaccines and diagnostics" Current Opinion in Chemical Biology (2001) 5:314-324
	BB	Parker and Tomer, "Epitope Mapping by a Combination of Epitope Excision and MALDI-MS" Methods in Molecular Biology, 146: 184-201
	BC	Nelson et al. "Monoclonal antibodies" Molecular Pathology, Accepted for publication February 8, 2000
	BD	Nussinov and Wolfson, "Efficient Computational Algorithms for Docking and for generating and matching a library of functional epitopes II. Computer Vision-based techniques for the generation and utilization of functional epitopes.(1999)Combinatorial Chemistry and High Throughput Screening 2: 261-269.
	BE	Rothbard and Taylor, "A sequence pattern common to T cell epitopes"93-100
	BF	De Groot et al. "From genome to vaccine: in silico predictions, ex vivo verification" Vaccine 19 (2001) 4385-4395.
	BG	Rammensee et al. "MHC ligands and peptide motifs: first listing" Immunogenetics (1995) 41: 178-228.
	BH	Schirle et al. "Identification of tumor-associated MHC class I ligands by a novel T cell-independent approach" Eur. J. immunol, (2000) 30: 2216-2225
	BI	Southwood et al. "Several Common HLA-DR Types share largely overlapping peptide binding repertoires" The Journal of Immunology, 1998, 160: 3363-3373.
	BJ	Singigaglia et al. "A malaria T-cell epitope recognized in association with most mouse and human MHC class II molecules" Nature Vol. 336 22/29 December 1988, 778-780
	BK	Chicz et al. "Specificity and Promiscuity among naturally processed peptides bound to HLA-DR Alleles" (1993) J. Exp. Med. 178: 27-79
	BL	Hammer et al. "Promiscuous and Allele-specific anchors in HLA-DR-Binding Peptides" (1993) Cell, vol. 197-203
	BM	Falk et al. "Pool sequencing of natural HLA-DR, DQ, and DP ligands reveals detailed peptide motifs, constraints of processing and general rules" Immunogenetics (1994) 39: 230-242
	BN	Alexander et al. " Serum interleukin 5 concentrations in atopic and non-atopic patients with glucocorticoid-dependent chronic severe asthma" Thorax (1994) 49:1231-1233.
	BO	Dempsey et al. "C3d of complement as a molecular adjuvant: bridging innate and acquired immunity" (1996) Science 271: 348
	BP	Lou and Kohler, "Enhanced molecular mimicry of CEA using photoaffinity crosslinked C3d peptide" Nature Biotechnology (1998) 16: 458-462
	BQ	Gregorius et al. "Hydrocoating: a new method for coupling biomolecules to solid phases" Journal of Immunological Methods (1995) 181: 65-73

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.